Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
BI 224436
Другие языки:

    BI 224436

    Подписчиков: 0, рейтинг: 0
    BI 224436
    BI 224436.svg
    Clinical data
    ATC code
    • none
    Legal status
    Legal status
    • Investigational
    Pharmacokinetic data
    Elimination half-life 7 hrs (simulated)
    Identifiers
    • (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl] [(2-methyl-2-propanyl)oxy]acetic acid
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C27H26N2O4
    Molar mass 442.515 g·mol−1
    3D model (JSmol)
    • CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4
    • InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1
    • Key:MIXIIJCBELCMCZ-VWLOTQADSA-N

    BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.

    Clinical trials were abandoned in advance of Phase 1.



    Новое сообщение